FDA Priority Review Status Refusals Show Need For Clinical Outcomes Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors who plan to seek priority review status need to show a superior effect on clinical outcomes, an examination of priority review requests rejected by FDA suggests